Business Wire

Norsk Titanium Adds Decorated Aerospace Executives to Top Technology Leadership Roles


Norsk Titanium AS, the world’s leading provider of aerospace-grade, titanium additive manufacturing technology today announced the appointment of Carl O. Johnson to the position of Senior Vice President – Technology, Engineering & Quality, and Rebecca A. McGrane to the position of Vice President & General Manager – Technology Center.

This Smart News Release features multimedia. View the full release here:

Norsk Titanium Senior Vice President - Technology, Engineering & Quality Carl O. Johnson. (Photo: Bu ...

Norsk Titanium Senior Vice President - Technology, Engineering & Quality Carl O. Johnson. (Photo: Business Wire)

Carl O. Johnson joins Norsk Titanium from Northrop Grumman, where his 33-year career was highlighted by leading the execution of the U.S. Navy X-47B program to the first ever landing of an autonomous unmanned aircraft on an aircraft carrier – a historical achievement that won Johnson and his team the prestigious Robert J. Collier Trophy. Mr. Johnson received a second Collier Trophy for his executive leadership of the U.S. Air Force Global Hawk UAS Program, which was deemed the Most Significant Achievement in Aviation for the year 2000 by the National Aeronautic Association. His background in leading technology development, quality, and high performing teams brings significant depth to Norsk Titanium’s executive and technical ranks.

Rebecca A. McGrane joins Norsk Titanium from General Dynamics, where her 15-year career was highlighted by numerous accolades for engineering excellence including the Horizon Industry Award for Technical Achievement, the Certificate of Commendation from the United States Marine Corps, and the Women of Color Technology Rising Star Award for helping to shape the technology of the future. As Director of the Maneuver Collaboration Center for General Dynamics Land Systems, Ms. McGrane was responsible for the innovation, maturation, and transition to production of future ground combat vehicle technologies. Ms. McGrane’s background in advanced composites and materials science research bring new levels of leadership excellence to the company’s Norway-based Technology Center.

“The quality of executive talent we are able to attract and retain is a direct testament to the magnitude of change we are bringing to the manufacturing world,” said Norsk Titanium CEO Warren M. Boley Jr. “Carl and Rebecca have each demonstrated a lifelong dedication to the proliferation of advanced technology and we are thrilled they now bring their scientific leadership to strengthen the revolution we call Rapid Plasma Deposition™.”

Mr. Johnson and Ms. McGrane will lead the continued advancement of Norsk Titanium’s patented Rapid Plasma Deposition™ technology to support the world’s premier aerospace & defense manufacturers and their airframe cost reduction programs by replacing legacy forged and machined parts with game-changing structural RPD™ components.

Mr. Johnson holds a Master’s Degree in Mechanical Engineering from Colorado State University, a Master’s Degree in Business Administration from the University of California, Los Angeles, and a Bachelor’s Degree in Mechanical Engineering from Northern Arizona University.

Ms. McGrane holds a Master’s Degree in Engineering Science and Mechanics from Virginia Polytechnic Institute and State University, and a Bachelor’s Degree in Mechanical Engineering from Texas A&M University.

About Norsk Titanium AS

Norsk Titanium AS is the world’s pioneering supplier of aerospace-grade, additive manufactured, structural titanium components. The company is distinguished in the aviation industry by its patented Rapid Plasma Deposition™ (RPD™) process that transforms titanium wire into complex components suitable for structural and safety-critical applications. The Norsk Titanium research and development team is committed to displacing the inefficient forging process with a precision wire deposition technology embodying substantial savings for aerospace, defense, and commercial applications.

Contact information

Norsk Titanium AS
Chip Yates, +1-949-735-9463
VP of Marketing

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on